PixarBio Corporation Discusses NeuroRelease™ a Non-Addictive Morphine Replacement at the 2016 SeeThruEquity Conference in New York City on October 17, 2016

CAMBRIDGE, Mass.–(BUSINESS WIRE)– PixarBio Corporation announced today, they will be discussing
NeuroRelease™, a potential breakthrough morphine replacement,
non-opiate/opioid, non-addictive pain treatment at the 2016
SeeThruEquity Conference in New York City 11:00AM EST on October 17,
2016.

The NeuroRelease™ Platform: Non-Addictive and Non-opiate Treatment of
Pain
NeuroRelease™ is a morphine replacement, and non-addictive
pain platform for the surgical/hospital setting, for the battlefield, or
for acute and chronic pain. First product FDA approval for the platform
will be for a 14-day post-surgical pain treatment and it is expected in
late 2018.

Major Benefits of NeuroRelease™

• Effects only sensory signals
• No effect on locomotion nerve fibers, so patients can enter physical
  therapy quickly
• Maintains two-point discriminate touch so patients can function
• No effect on proprioception so no effect on a person feeling of
  well-being

Therefore, patients will maintain two-point discriminate touch, control
of their locomotion nerve fibers so they control voluntary movement to
enter rehabilitation quickly with a non-addictive morphine replacement.
PixarBio’s NeuroRelease™ pain platform also includes 4-8 hour, 3-day,
7-day, 14-day and 90-Day pain treatments all have expected FDA approvals
in 2020. NeuroRelease™ is biodegradable, and it’s non-toxic so
NeuroRelease™ can be re-injected to extend treatment timelines.

The acquisition of BMP Holdings will be finalized on Saturday October
22, 2016 and public trading of the new PixarBio Corporation will begin
on Monday October 24, 2016.

PixarBio Corporation was awarded the Boston Business Journal’s « 2016
Best Places to Work ». The award recognizes PixarBio as one of the
region’s best firms, offering the greatest professional opportunities
and work environments to innovate.

About the SeeThruEquity Conference in New York City
SeeThruEquity
is the premier and unbiased provider of microcap equity research and
well-run, institutional and high net worth investor focused conferences.
Since our founding in 2011, STE has been committed to its core mission:
providing impactful, high quality research on uncovered and
under-covered microcap stocks. For more information about the
SeeThruEquity Conference visit: http://www.steconference.com/.

About PixarBio Corporation
PixarBio is a specialty
pharmaceutical/biotechnology company focused on pre-clinical and
commercial development of novel neurological drug delivery systems for
post-operative pain. PixarBio researches and develops targeted
delivery systems for drugs, cells, or biologics to treat pain, epilepsy,
Parkinson’s disease, and spinal cord injury. Our lead product platform,
NeuroRelease™, has achieved sustained therapeutic release of non-opiate
drugs for post-operative, acute and chronic pain in pre-clinical models.
For more information, visit www.pixarbio.com.

Safe Harbor Statement
This announcement includes
“forward-looking statements” within the meaning of the safe harbor
provisions of the United States Private Securities Litigation Reform Act
of 1995. These statements are based upon the current beliefs and
expectations of PixarBio’s management and are subject to significant
risks and uncertainties. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of Biotech and
medical device industry regulation and health care legislation in the
United States and internationally; global trends on cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development, including
obtaining regulatory approval; PixarBio’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk;
dependence on the effectiveness of PixarBio’s patents and other
protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.

PixarBio Corp undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be obtained through PixarBio’s Corp HQ at 200 Boston Ave,
Suite 1875 in Medford, MA 02155. PixarBio Corp is a private corporation.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005700/en/